Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Apelin vs Larazotide
An educational, source-based comparison of Apelin and Larazotide — how each peptide works, what it's researched for, and what to know before going deeper.
An endogenous peptide ligand for the APJ receptor, widely expressed in cardiovascular and metabolic tissues. Research indicates roles in cardiac contractility, angiogenesis, blood pressure regulation, and insulin sensitivity.
- Heart failure and cardiac contractility
- Pulmonary arterial hypertension
- Insulin sensitivity and glucose uptake
- Angiogenesis and vascular repair
- • Primarily preclinical and early clinical research.
- • Not FDA-approved for any indication.
An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.
- Celiac disease (Phase 3 completed)
- Intestinal barrier function ('leaky gut' research)
- Environmental enteropathy
- • Not yet FDA-approved.
- • Investigational; physician oversight required.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Apelin | Apelin in heart failure: a new therapeutic target | Journal of the American College of Cardiology | 2019 | Reviewed cardioprotective mechanisms and therapeutic potential in heart failure. |
| Apelin | Apelin improves insulin sensitivity in obese models | Diabetes | 2014 | Enhanced glucose uptake and insulin signaling in adipose and muscle tissue. |
| Larazotide | Larazotide acetate for persistent symptoms of celiac disease | Gastroenterology | 2015 | Reduced symptom severity in gluten-exposed celiac patients on gluten-free diet. |
Side-effect & safety grid
- Primarily preclinical and early clinical research.
- Not FDA-approved for any indication.
- Not yet FDA-approved.
- Investigational; physician oversight required.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Apelin vs Larazotide — Key differences
- Class: Apelin is classified as Cardiovascular · Metabolic, while Larazotide is Gastrointestinal · Barrier.
- Primary research focus: Apelin — heart failure and cardiac contractility; Larazotide — celiac disease (phase 3 completed).
- Tag: Cardiovascular · Metabolic vs Gut.